Departamento de Psiquiatria, Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.
Division of Substance Abuse, New York State Psychiatric Institute (NYSPI), Columbia University, New York, NY, USA.
Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255. doi: 10.1007/s00213-020-05563-3. Epub 2020 Jun 29.
Agonist-based pharmacologic intervention is an accepted approach in treatment of opioid and tobacco use disorders.
We conducted a systematic review and meta-analysis to evaluate usefulness of an agonist approach as treatment of (psycho)stimulant use disorder (PSUD).
We reviewed PubMed/Medline, LILACS, and ClinicalTrials.gov databases searching for randomized, double-blind, placebo-controlled, parallel-design studies evaluating outcomes of individuals treated for cocaine- or amphetamine-type substance use disorder. We combined results of all trials that included the following prescription psychostimulants (PPs): modafinil, methylphenidate, or amphetamines (mixed amphetamine salts, lisdexamphetamine, and dextroamphetamine). The combined sample consisted of 2889 patients. Outcomes of interest included the following: drug abstinence (defined as 2-3 weeks of sustained abstinence and the average maximum days of consecutive abstinence), percentage of drug-negative urine tests across trial, and retention in treatment. We conducted random-effects meta-analyses and assessed quality of evidence using the GRADE system.
Thirty-eight trials were included. Treatment with PPs increases rates of sustained abstinence [risk ratio (RR) = 1.45, 95% confidence interval (CI) = (1.10, 1.92)] and duration of abstinence [mean difference (MD) = 3.34, 95% CI = (1.06, 5.62)] in patients with PSUD, particularly those with cocaine use disorder (very low-quality evidence). Prescription amphetamines were particularly efficacious in promoting sustained abstinence in patients with cocaine use disorder [RR = 2.44, 95% CI = (1.66, 3.58)], and higher doses of PPs were particularly efficacious for treatment of cocaine use disorder [RR = 1.95, 95% CI = (1.38, 2.77)] (moderate-quality evidence). Treatment with prescription amphetamines also yielded more cocaine-negative urines [MD = 8.37%, 95% CI = (3.75, 12.98)]. There was no effect of PPs on the retention in treatment.
Prescription psychostimulants, particularly prescription amphetamines given in robust doses, have a clinically significant beneficial effect to promote abstinence in the treatment of individuals with PSUD, specifically the population with cocaine use disorder.
基于激动剂的药物干预是治疗阿片类药物和烟草使用障碍的一种公认方法。
我们进行了系统评价和荟萃分析,以评估激动剂方法作为(精神)兴奋剂使用障碍(PSUD)治疗的有效性。
我们检索了 PubMed/Medline、LILACS 和 ClinicalTrials.gov 数据库,以评估治疗可卡因或安非他命类物质使用障碍的个体的结局的随机、双盲、安慰剂对照、平行设计研究。我们合并了包括以下处方兴奋剂(PPs)的所有试验的结果:莫达非尼、哌甲酯或安非他命(混合安非他命盐、利右苯丙胺和右旋苯丙胺)。合并样本包括 2889 名患者。感兴趣的结局包括以下内容:药物戒断(定义为持续 2-3 周的戒断和连续戒断的最长天数)、试验期间药物阴性尿液检测的百分比以及治疗保留率。我们进行了随机效应荟萃分析,并使用 GRADE 系统评估证据质量。
纳入了 38 项试验。PPs 的治疗可提高 PSUD 患者的持续戒断率[风险比(RR)=1.45,95%置信区间(CI)=(1.10,1.92)]和戒断持续时间[平均差(MD)=3.34,95%CI=(1.06,5.62)],尤其是可卡因使用障碍患者(极低质量证据)。处方安非他命特别有效地促进可卡因使用障碍患者的持续戒断[RR=2.44,95%CI=(1.66,3.58)],较高剂量的 PPs 特别有效地治疗可卡因使用障碍[RR=1.95,95%CI=(1.38,2.77)](中等质量证据)。处方安非他命的治疗还产生了更多的可卡因阴性尿液[MD=8.37%,95%CI=(3.75,12.98)]。PPs 对治疗保留率没有影响。
处方兴奋剂,特别是以大剂量给予的处方安非他命,对促进 PSUD 个体的戒断有显著的临床获益,特别是可卡因使用障碍患者。